Comparison of Eprosartan/HCT Versus Enalapril/HCT in Hypertensives With Type II Diabetes
A Multi-Center, Double-Blind, Randomized Study Comparing the Efficacy of Combination Therapy of Eprosartan Respectively Ramipril With Low-Dose Hydrochlorothiazide and Moxonidine on Blood Pressure Levels in Patients With Hypertension and Associated Diabetes Mellitus Type 2
2 other identifiers
interventional
440
9 countries
63
Brief Summary
This study is to demonstrate the superiority of combination of eprosartan/HCTZ versus ramipril/HCTZ.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable hypertension
63 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2004
CompletedFirst Submitted
Initial submission to the registry
September 8, 2005
CompletedFirst Posted
Study publicly available on registry
September 12, 2005
CompletedJanuary 30, 2009
January 1, 2009
September 8, 2005
January 29, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Blood pressure reduction
Secondary Outcomes (1)
Comparison of responder rates
Interventions
Eligibility Criteria
You may qualify if:
- essential hypertension,
- diabetes type 2
You may not qualify if:
- severe cardiovascular disease,
- grade 3 hypertension,
- secondary hypertension,
- abnormal liver enzymes
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (63)
Site 26
Calgary, Canada
Site 27
Montreal, Canada
Site 30
Québec, Canada
Site 31
Thornhill, Canada
Site 28
Vancouver, Canada
Site 29
Winnipeg, Canada
Site 39
Holbæk, Denmark
Site 38
Roskilde, Denmark
Site 40
Viborg, Denmark
Site 4
Anzin, France
Site 3
Blois, France
Site 10
Chemellier, France
Site 11
Cholet, France
Site 15
Cholet, France
Site 16
Cholet, France
Site 14
La Jubaudière, France
Site 13
Le Mesnil-en-Vallée, France
Site 7
Mûrs-Erigné, France
Site 12
Saint Pierre Montlim, France
Site 9
Saumur, France
Site 8
Segré, France
Site 6
Thouars, France
Site 2
Tours, France
Site 5
Vieux-Condé, France
Site 20
Bad Muenster, Germany
Site 22
Flörsheim, Germany
Site 19
Kirweiler, Germany
Site 21
Lambrecht, Germany
Site 25
Lindau, Germany
Site 24
Lutherstadt, Germany
Site 18
Lüneburg, Germany
Site 17
Riesa, Germany
Site 23
Waldbrunn, Germany
Site 62
Bologna, Italy
Site 60
Napoli, Italy
Site 58
Padua, Italy
Site 59
Palermo, Italy
Site 63
Pavia, Italy
Site 61
Pisa, Italy
Site 64
Torino, Italy
Site 43
Ålesund, Norway
Site 42
Bergen, Norway
Site 44
Horten, Norway
Site 41
Skedsmokorset, Norway
Site 55
Badajoz, Spain
Site 51
Badalona, Spain
Site 56
Barcelona, Spain
Site 57
Barcelona, Spain
Site 54
Ciudad Real, Spain
Site 53
Granada, Spain
Site 52
Madrid, Spain
Site 48
Ängelholm, Sweden
Site 47
Gothenburg, Sweden
Site 46
Helsingborg, Sweden
Site 45
Kristianstat, Sweden
Site 50
Malmo, Sweden
Site 49
Stockholm, Sweden
Site 33
Aberdeen, United Kingdom
Site 36
Bath, United Kingdom
Site 37
Liverpool, United Kingdom
Site 34
Manchester, United Kingdom
Site 32
Oldham, United Kingdom
Site 35
Rugby, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Global Clinical Director Solvay
Solvay Pharmaceuticals
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
September 8, 2005
First Posted
September 12, 2005
Study Start
October 1, 2004
Last Updated
January 30, 2009
Record last verified: 2009-01